Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML)

Print

Rates of response and survival at 5 years in trials of chemotherapy, interferon and imatinib for CML
 
«Back

Return to Profile




Home
New On This Site
Products & Services
Company A-Z
Industry Projects
White Papers
Jobs & Careers
Press Releases
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area

For every phase of your drug development